MT-001 / Mentari Therapeutics - LARVOL DELTA

A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled Single Ascending Dose Study of MT-001 in Adult Participants (ANZCTR) - P1 | N=40 | Not yet recruiting | Sponsor: Mentari Therapeutics, Inc.

First-in-human • New P1 trial • CNS Disorders • Migraine

Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline (PRNewswire) - "The financing, based on current plans, extends Mentari's cash runway into 2029 and through Phase 2a readouts on each of the two PACAP-targeted lead programs, including MT-002. Additionally, it supports the clinical development of Mentari's broader migraine prevention pipeline."

Financing • Migraine